Veracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow VCYT
Veracyte, Inc. (VCYT) EV/Sales
As of 16 October 2026, Veracyte, Inc. (VCYT) trades at a EV/Sales of 5.3×. Over the past ten years it has ranged from 1.7× (March 2016) to 33.9× (February 2021); the current reading is higher than 56% of that period. That is in line with the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.6× | (8.89%) |
| FY2024 | 6.2× | 25.02% |
| FY2023 | 4.9× | 1.03% |
| FY2022 | 4.9× | (59.23%) |
| FY2021 | 11.9× | (37.88%) |
| FY2020 | 19.2× | 104.64% |
| FY2019 | 9.4× | 109.32% |
| FY2018 | 4.5× | 46.30% |
| FY2017 | 3.1× | 2.98% |
| FY2016 | 3.0× | (4.45%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.5× | 91.17% |
| Mar 2026 | 3.9× | (29.99%) |
| Dec 2025 | 5.6× | 18.65% |
| Sep 2025 | 4.7× | 25.68% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDNT RadNet, Inc. compare | 2.6× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| VCYT Veracyte, Inc. | 5.3× |
| SHC Sotera Health Company compare | 5.7× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| GRAL GRAIL, Inc. compare | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)